首页> 外国专利> Perm selective membrane for treating vascular calcification in chronic hemodialysis patients

Perm selective membrane for treating vascular calcification in chronic hemodialysis patients

机译:烫发选择膜治疗慢性血液透析患者的血管钙化

摘要

#$%^&*AU2018260858B220181220.pdf#####Abstract The present disclosure relates to a hemodialysis membrane for the treatment of vascular calcification in hemodialysis patients, especially in chronic hemodialysis patients. The 5 present disclosure further relates to methods of treating vascular calcification in hemodialysis patients, wherein the hemodialysis membrane is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a 0 MWCO of between 170-320 kD or that the hemodialysis membrane comprises at least one hydrophobic polymer and at least one hydrophilic polymer and has a MWRO of between 8.5 kD and 14.0 kD and a MWCO of between 55 kD and 130 kD. (Fig. 4) 5863330_2 (GHMatters) P98259.AU.14/7 A ALP activity C Calcium deposition 150- 20001 100- -. E 100-- *-50- "''''.... _ __ 0=L 0 0 Conventional HCO Conventional HCO B D 1.0- 1.00.8- 0.800.6- 0.60.4- 0.40.2- 0.20.0o 0.0 Conventional HCO Conventional HCO Figure 4
机译:#$%^&* AU2018260858B220181220.pdf #####抽象本公开涉及一种血液透析膜用于血液透析中的血管钙化患者,尤其是慢性血液透析患者。的5本公开进一步涉及治疗方法血液透析患者的血管钙化,其中血液透析膜的特征在于它包含至少一种疏水性聚合物和至少一种亲水性聚合物,其MWRO为15至20 kD,170-320 kD之间的0 MWCO或血液透析膜包含至少一种疏水聚合物和至少一种亲水聚合物,MWRO在8.5 kD和14.0之间kD和MWCO在55 kD和130 kD之间。(图4)5863330_2(GHMatters)P98259.AU.14/7ALP活性C钙沉积150- 20001100--。> E 100-- *-50-“''''...._ __0= L0 0常规HCO常规HCOD1.0- 1.00.8- 0.800.6- 0.60.4- 0.40.2- 0.20.0o 0.0常规HCO常规HCO图4

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号